Results 11 to 20 of about 17,033 (261)
Direct-acting antivirals and visceral leishmaniasis: a case report [PDF]
BMC Infectious Diseases, 2019 Background Visceral leishmaniasis is a vector-borne parasitic disease caused by protozoa belonging to the genus Leishmania. The clinical presentation of visceral leishmaniasis strictly depends on the host immunocompetency, whereas depressive conditions ...
Claudia Colomba +7 more
doaj +4 more sources
Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis [PDF]
Scientifica, 2012 The development and evaluation of antiviral agents through carefully designed clinical trials over the last 25 years have heralded a new dawn in the treatment of patients chronically infected with the hepatitis B and C viruses, but not so for the D virus
Peter Karayiannis
doaj +3 more sources
Management of Direct‐Acting Antiviral Failures [PDF]
Clinical Liver Disease, 2020 Answer questions and earn CME.
Maryam, Alimirah +2 more
openaire +2 more sources
Direct-acting antivirals for chronic hepatitis C [PDF]
Cochrane Database of Systematic Reviews, 2016 Millions of people worldwide suffer from hepatitis C, which can lead to severe liver disease, liver cancer, and death. Direct-acting antivirals (DAAs) are relatively new and expensive interventions for chronic hepatitis C, and preliminary results suggest that DAAs may eradicate hepatitis C virus (HCV) from the blood (sustained virological response ...
Jakobsen, Janus C. +15 more
openaire +8 more sources
Acta Scientiarum. Health Sciences, 2023 To report the sociodemographic and clinical profile of patients treated with direct-action antivirals (DAAs). Patients infected with hepatitis C virus in current treatment were followed up in a pharmaceutical office.
Karem Aline Pegoraro +3 more
doaj +1 more source
Therapeutic Advances Against ZIKV: A Quick Response, a Long Way to Go
Pharmaceuticals, 2019 Zika virus (ZIKV) is a mosquito-borne flavivirus that spread throughout the American continent in 2015 causing considerable worldwide social and health alarm due to its association with ocular lesions and microcephaly in newborns, and Guillain−Barr&
Juan-Carlos Saiz
doaj +1 more source
The occurrence of thrombotic thrombocytopenic purpura during treatment of HCV with direct-acting antiviral agents [PDF]
African Journal of Gastroenterology and Hepatology, 2018 Background and aim Experts have reported thrombocytopenia is linked to chronic liver disease in up to 70% of patients with advanced fibrosis and portal hypertension. The occurrence of thrombotic thrombocytopenic purpura (TTP) with HCV infection is a rare
Amr Hanafy, Waseem Seleem, Salem Mohamed
doaj +1 more source
SHARED: An International Collaboration to Unravel Hepatitis C Resistance
Viruses, 2021 The advent of direct-acting antivirals (DAAs) has transformed the treatment landscape of hepatitis C [...]
Anita Y.M. Howe +12 more
doaj +1 more source
New horizons in hepatitis C antiviral therapy with direct-acting antivirals [PDF]
Hepatology, 2013 Abstract Most direct-acting antivirals (DAAs) that are being developed as therapy against hepatitis C virus target the NS3/4A protease, the NS5A protein, and the NS5B polymerase. The latter enzyme offers different target sites: the catalytic domain for nucleos(t)ide analogues as well as a number of allosteric sites ...
Alessio, Aghemo, Raffaele, De Francesco
openaire +2 more sources
Pharmaceuticals, 2023 Combining antiviral drugs with different mechanisms of action can help prevent the development of resistance by attacking the infectious agent through multiple pathways.
Liliana Betancur-Galvis +4 more
doaj +1 more source